UK markets open in 2 hours 15 minutes
  • NIKKEI 225

    29,648.88
    +27.89 (+0.09%)
     
  • HANG SENG

    28,623.90
    -276.93 (-0.96%)
     
  • CRUDE OIL

    63.08
    -0.07 (-0.11%)
     
  • GOLD FUTURES

    1,739.50
    +3.20 (+0.18%)
     
  • DOW

    33,730.89
    +53.62 (+0.16%)
     
  • BTC-GBP

    45,965.89
    -472.91 (-1.02%)
     
  • CMC Crypto 200

    1,380.53
    +4.76 (+0.35%)
     
  • ^IXIC

    13,857.84
    -138.26 (-0.99%)
     
  • ^FTAS

    3,964.67
    +25.36 (+0.64%)
     

Major Depressive Disorder - Epidemiology Forecast to 2029

ReportLinker
·3-min read

Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems (Mayo Clinic, 2018).

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Major Depressive Disorder - Epidemiology Forecast to 2029" - https://www.reportlinker.com/p06034994/?utm_source=GNW
MDD is characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and overeating or loss of appetite that can last from days to months, which alternates with episodes of wellness (MedlinePlus, 2020).

MDD is a highly debilitating condition associated with substantial morbidity, and an enormous social and economic burden (Kessler and Bromet, 2013).The condition affects the thoughts, feelings, behavior, and physical health of an individual, leading to a range of psychological, physical, and social problems.

Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental, and psychological factors that potentially increase the risk of MDD (Kessler and Bromet, 2013; Mayo Clinic, 2018; National Institute of Mental Health, 2018; MedlinePlus, 2020).

In the 8MM, epidemiologists forecast that the 12-month total prevalent cases of MDD will increase from 53,373,325 12-month total prevalent cases in 2019 to 55,363,640 12-month total prevalent cases in 2029, at an Annual Growth Rate (AGR) of 0.37%. The US will have the highest number of 12-month total prevalent cases of MDD among the 8MM throughout the forecast period, while Canada will have the lowest number of 12-month total prevalent cases of MDD.

Scope
- Major depressive disorder (MDD) Epidemiology Report and Model provide an overview of the risk factors and the global and historical trends for MDD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
- The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases of MDD based on the American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. The 12-month total prevalent cases of MDD (including diagnosed and undiagnosed) are further segmented by age, sex, and severity (mild, moderate, and severe).
- This epidemiology forecast for MDD is supported by historical data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast total prevalent cases of MDD across these markets.
- The MDD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy
The MDD Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MDD therapeutics in each of the markets covered.
- Understand magnitude of MDD by severity.
Read the full report: https://www.reportlinker.com/p06034994/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001